Loading
A phase 3 trial testing Clifutinib in acute myeloid leukaemia, now recruiting.
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML is a phase 3 interventional study registered as NCT05586074, led by Sunshine Lake Pharma, and recruiting on the registry. Official title: HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia: a Multicenter, Open-label, Randomised Phase 3 Trial. Planned enrolment is 324 participants (estimated). The study started in 2023-03-03 and primary completion is expected in 2027-11-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Clifutinib, Sunshine Lake Pharma (HEC), Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/